Multimedia content is supported by an unrestricted educational grant from:

Scientific Agenda

Mycology workshop
Deanna A. Sutton, PhD and Annette W. Fothergill, MA, MBA

Session I: Risk factors and epidemiology
Moderators: Jan E. Patterson, MD and John E. Edwards, Jr., MD

Epidemiological trends in invasive fungal infections: The TRANSNET database
Peter G. Pappas, MD

Outbreak of keratitis with Fusarium spp
Benjamin J. Park, MD

Notable trends in antifungal drug resistance
Michael A. Pfaller, MD

All aspergilli are not created equal
Kieren A. Marr, MD

Underappreciated risk factors for invasive mould infections
Dimitrios P. Kontoyiannis, MD, ScD

Session II: Bridging the gap
Moderator: Mahmoud Ghannoum, PhD, EMBA

From bunnies to babies: Bridging the gap in candidiasis of the central nervous system
William W. Hope, MD

From guinea pigs to humans: What have we learned regarding pulmonary aspergillosis?
Thomas F. Patterson, MD, FACP

Session III: Diagnosis
Moderator: Jay A. Fishman, MD

Novel diagnostic tests for invasive mould infections (tissues and fluids)
Shigeru Kohno, MD, PhD

Radiology of fungal infections: When can you tell whether the patient is improving?
Ronald C. Walker, MD

PET/CT: A new and powerful imaging tool for the diagnosis of serious infections, even during severe immunosuppression
Ronald C. Walker, MD

Session IV: Management of fungal infections I: Candidiasis
Moderator: Carol A. Kauffman, MD

Genitourinary candidiasis: An update on pathogenesis and management
Jack D. Sobel, MD

Risk factors for invasive candidiasis in the ICU: A risk-stratification strategy for prophylactic and pre-emptive therapy
Coleman M.F. Rotstein, MD, FRCPC, FACP

How I treat hematogenous candidiasis
John E. Edwards, Jr., MD

Session V: Management of fungal infections II: Aspergillosis & other invasive infections
Moderator: John R. Graybill, MD

Epidemiology and management of Zygomycosis
Carol A. Kauffman, MD

Update on other mould infections: Fusarium, other agents of hyalohyphomycosis and phaeohyphomycosis              
Marcio Nucci, MD, PhD

Endemic mycoses and cryptococcosis
Robert W. Bradsher, MD

Session VI: Antifungal trial design
Moderators: James I. Ito, MD and Jack D. Sobel, MD

Candidiasis: Why we need to change our trial strategy
Luis Ostrosky-Zeichner, MD, FACP

Antifungal trial design for mould-active agents: Time to break the mold
Elias J. Anaissie, MD

Pharmacodynamics: A frequently forgotten (but essential) tool of antifungal trial design
George L. Drusano, MD

Pharmacogenomics of antifungal agents: An update
David R. Andes, MD

Special lecture: TH1-TH2 in aspergillosis
David A. Stevens, MD

Session VII: Management of fungal infections III: The future of antifungal therapy?
Moderator: William Dismukes, MD

Mould active azoles: Interaction with immunomodulators and anti-cancer agents, comparative pharmacokinetics/dynamics to include CNS penetration, food effect, IV/PO
Paul O. Gubbins, PharmD

Echinocandins: Comparative pharmacokinetics/dynamics of caspofungin, micafungin and anidulafungin with implications for trial design and patient care
Thomas J. Walsh, MD

Polyenes: “Do the old dogs have new tricks?"
John R. Graybill, MD

Session VIII: Management of fungal infections in various hosts – Lessons learned
Moderator: Kieren A. Marr, MD

Immune reconstitution syndromes in invasive fungal infections
John R. Perfect, MD

Solid organ transplantation
Jay A. Fishman, MD

Leukemia and bone marrow transplantation
John R. Wingard, MD

Chronic granulomatous disease
Brahm H. Segal, MD

Speaking words of wisdom: My 30-year experience with fungal infections
William E. Dismukes, MD